Gamma-aminobutyric acid type A receptor, benzodiazepine binding site (GABA_A receptor, BZD site)

The **benzodiazepine site on the gamma-aminobutyric acid type A (GABA_A) receptor** is a highly specific allosteric binding site located at the interface of the α and γ subunits of the GABA_A receptor, a pentameric ligand-gated ion channel that mediates the rapid inhibitory effects of GABA in the central nervous system[1][2][4][5][6][7]. Benzodiazepines and related drugs bind to this site and act as positive allosteric modulators, increasing the frequency (but not the duration) of chloride channel opening in response to GABA, leading to neuronal hyperpolarization and decreased excitability[1][3][4][7]. The GABA_A receptor is composed primarily of two α, two β, and one γ subunit; the benzodiazepine site exists only in receptors containing specific α (particularly α1, α2, α3, or α5) and γ subunits[2][6]. This site is a key target for numerous anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant drugs, as well as a small number of non-benzodiazepine drugs with similar effects[5][6]. Dysfunction or altered sensitivity of the GABA_A benzodiazepine site has been implicated in a variety of psychiatric and neurological disorders, guiding both diagnosis and drug development[3][6].

Other names

Benzodiazepine receptorGABA-benzodiazepine receptor complexGABA_A benzodiazepine siteBZD site on GABA_A receptor

Positive allosteric modulation (increases frequency of chloride channel opening upon GABA binding for benzodiazepines); Negative allosteric modulation (certain drugs decrease channel activity or counteract positive modulators)